ARK Investment Management LLC cut its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Get Rating) by 2.4% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 399,956 shares of the company's stock after selling 9,628 shares during the quarter. ARK Investment Management LLC's holdings in Cellebrite DI were worth $1,928,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently bought and sold shares of CLBT. Swiss National Bank increased its holdings in shares of Cellebrite DI by 7.6% during the 1st quarter. Swiss National Bank now owns 89,000 shares of the company's stock valued at $570,000 after purchasing an additional 6,300 shares in the last quarter. Josh Arnold Investment Consultant LLC purchased a new position in shares of Cellebrite DI during the 1st quarter valued at approximately $64,000. Blair William & Co. IL purchased a new position in shares of Cellebrite DI during the 4th quarter valued at approximately $135,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Cellebrite DI during the 1st quarter valued at approximately $127,000. Finally, Diametric Capital LP purchased a new position in shares of Cellebrite DI during the 4th quarter valued at approximately $209,000. 20.41% of the stock is owned by hedge funds and other institutional investors.
Get Cellebrite DI alerts:Cellebrite DI Stock Down 1.9 %
Shares of CLBT opened at $4.29 on Tuesday. Cellebrite DI Ltd. has a 52-week low of $4.10 and a 52-week high of $11.60. The firm's fifty day moving average is $5.09 and its two-hundred day moving average is $5.38. The stock has a market cap of $807.89 million, a PE ratio of 5.79, a price-to-earnings-growth ratio of 10.34 and a beta of 0.87.
Wall Street Analyst Weigh In
CLBT has been the subject of several recent research reports. Cowen cut their target price on shares of Cellebrite DI from $13.00 to $10.00 and set an "outperform" rating for the company in a report on Friday, August 12th. Bank of America cut shares of Cellebrite DI from a "buy" rating to a "neutral" rating and dropped their price target for the company from $6.50 to $6.00 in a research note on Friday, August 12th. Needham & Company LLC lifted their price target on shares of Cellebrite DI from $6.00 to $6.50 and gave the company a "buy" rating in a research note on Thursday, August 11th. Cowen dropped their price target on shares of Cellebrite DI from $13.00 to $10.00 and set an "outperform" rating on the stock in a research note on Friday, August 12th. Finally, William Blair cut shares of Cellebrite DI from an "outperform" rating to a "market perform" rating in a research note on Friday, August 12th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $9.71.About Cellebrite DI
(Get Rating)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.
Featured Articles
- Get a free copy of the StockNews.com research report on Cellebrite DI (CLBT)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT – Get Rating).
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.